New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.
The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA.
Vandana
V
Abramson
Carlos L
CL
Arteaga
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D000077341:Lapatinib; D058990:Molecular Targeted Therapy / Q000379:methods*; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D015398:Signal Transduction; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
Cancer Res. 2008 Apr 1;68(7):2340-8
18381441
Clin Cancer Res. 2008 Dec 1;14(23):7861-70
19047115
Am J Pathol. 2010 Oct;177(4):1647-56
20813970
Cancer Res. 2002 Jul 15;62(14):4132-41
12124352
Cancer Cell. 2009 May 5;15(5):429-40
19411071
N Engl J Med. 2006 Feb 23;354(8):809-20
16495393
Cancer Cell. 2004 Aug;6(2):117-27
15324695
N Engl J Med. 2008 Mar 27;358(13):1409-11
18367751
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
J Clin Oncol. 2006 Jun 20;24(18):2786-92
16782917
J Clin Oncol. 2010 Mar 1;28(7):1138-44
20124182
J Clin Oncol. 2003 Jan 1;21(1):46-53
12506169
Clin Cancer Res. 2010 May 1;16(9):2688-95
20406840
J Clin Oncol. 2005 Jun 1;23(16):3676-85
15738535
J Clin Oncol. 2009 Apr 20;27(12):1999-2006
19289619
J Clin Oncol. 2010 Mar 1;28(7):1124-30
20124187
Clin Cancer Res. 2005 Sep 15;11(18):6598-607
16166438
Breast Cancer Res Treat. 2005 Sep;93(1):3-11
16184453
EMBO J. 2006 Jul 12;25(13):3234-44
16794579
Nat Rev Cancer. 2009 Aug;9(8):550-62
19629070
Sci Transl Med. 2010 Jan 27;2(16):16ra7
20371474
Breast Cancer Res Treat. 2011 Jul;128(2):347-56
20730488
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
17440164
Cancer Res. 2008 Jul 15;68(14):5878-87
18632642
Cancer Cell. 2007 Oct;12(4):395-402
17936563
Curr Opin Cell Biol. 2009 Apr;21(2):194-8
19201591
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304
20007781
Cancer Res. 2010 Mar 15;70(6):2485-94
20215504
Clin Cancer Res. 2009 Dec 1;15(23):7381-8
19920100
Lancet. 2007 Jan 6;369(9555):29-36
17208639
Clin Breast Cancer. 2005 Aug;6(3):240-6
16137435
Anticancer Res. 2006 Jan-Feb;26(1B):647-53
16739334
Cancer Res. 2008 Nov 15;68(22):9280-90
19010901
Diagn Mol Pathol. 2009 Mar;18(1):22-9
19214112
J Clin Oncol. 2010 Mar 10;28(8):1301-7
20142587
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8
15194824
Cancer Cell. 2002 Aug;2(2):127-37
12204533
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8
12853564
Cancer Res. 2009 Dec 15;69(24):9330-6
19934333
Cancer Cell. 2010 Aug 9;18(2):160-70
20708157
J Clin Oncol. 2006 Apr 20;24(12):1831-8
16549824
J Clin Oncol. 2009 Mar 10;27(8):1323-33
19204209
Cancer Res. 2008 Oct 1;68(19):8022-30
18829560
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
J Clin Oncol. 2002 Jul 15;20(14):3095-105
12118023
Lancet. 2010 Jan 30;375(9712):377-84
20113825
J Clin Oncol. 2009 Dec 1;27(34):5693-9
19884553
Clin Cancer Res. 2007 Feb 15;13(4):1198-207
17317830
Oncogene. 2007 May 24;26(24):3503-10
17173075
J Clin Oncol. 2005 Apr 10;23(11):2469-76
15753463
J Biol Chem. 2001 Nov 9;276(45):42153-61
11546794
J Clin Oncol. 2009 Dec 1;27(34):5700-6
19884543
Science. 2007 May 18;316(5827):1039-43
17463250
Cancer Res. 2008 Nov 15;68(22):9221-30
19010894
J Clin Oncol. 2011 Feb 1;29(4):398-405
21172893
J Clin Oncol. 2010 Jun 1;28(16):2698-704
20421541
J Clin Oncol. 2008 Jun 20;26(18):2999-3005
18458039